Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer.

Takeuchi H, Ohori M, Tachibana M.

Mol Clin Oncol. 2017 Feb;6(2):249-254. doi: 10.3892/mco.2016.1116. Epub 2016 Dec 22.

2.

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.

Dijkstra S, Witjes WP, Roos EP, Vijverberg PL, Geboers AD, Bruins JL, Smits GA, Vergunst H, Mulders PF.

Springerplus. 2016 May 17;5:653. doi: 10.1186/s40064-016-2280-8. eCollection 2016.

3.

Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer.

Chiang AS, Loblaw DA, Jethava V, Sethukavalan P, Zhang L, Vesprini D, Mamedov A, Nam R, Klotz L.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):450-3. doi: 10.5489/cuaj.262.

4.

Biochemistry on the human scale.

Sikaris K.

Clin Biochem Rev. 2010 Nov;31(4):121-8. No abstract available.

5.

PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB.

Eur Urol. 2008 Nov;54(5):1073-80. doi: 10.1016/j.eururo.2008.06.076. Epub 2008 Jul 2.

6.

Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?

Cabrera AR, Coakley FV, Westphalen AC, Lu Y, Zhao S, Shinohara K, Carroll PR, Kurhanewicz J.

Radiology. 2008 May;247(2):444-50. doi: 10.1148/radiol.2472070770.

7.

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.

Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group.

J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6. doi: 10.1016/j.juro.2008.01.099. Epub 2008 Apr 18.

8.

A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy.

Tareen B, Summers JL, Jamison JM, Neal DR, McGuire K, Gerson L, Diokno A.

Int J Med Sci. 2008 Mar 24;5(2):62-7.

9.
10.

What's a man to do? Treatment options for localized prostate cancer.

Pickles T.

Can Fam Physician. 2004 Jan;50:65-72. Review.

Supplemental Content

Support Center